ライフサイエンスコーパス: antibody therapy

1 epresent particularly attractive targets for antibody therapy.

2 ure, is a suitable target for neutralization antibody therapy.

3 population for developing neutropenia after antibody therapy.

4 ich are currently inaccessible to monoclonal antibody therapy.

5 mmune response and to synergize with passive antibody therapy.

6 ry abnormalities, which could be targeted by antibody therapy.

7 tive or resistant to Her-2-targeted drugs or antibody therapy.

8 in the spleen was unaffected by OX40 agonist antibody therapy.

9 ols to study STEAP-1 susceptibility to naked antibody therapy.

10 asize to the brain, which is inaccessible to antibody therapy.

11 atory cells had to be blocked with anti-CD25 antibody therapy.

12 s represent potential targets for monoclonal antibody therapy.

13 h rheumatoid arthritis treated with anti-TNF antibody therapy.

14 of recent adverse events with costimulatory antibody therapy.

15 ucidate the mechanism of action of anti-PSCA antibody therapy.

16 but did not affect the outcome of monoclonal antibody therapy.

17 with or after HER-2/neu-specific monoclonal antibody therapy.

18 osis and for selecting tumors for monoclonal antibody therapy.

19 myelotoxicity for non-marrow-targeting (90)Y-antibody therapy.

20 s, even without the routine use of induction antibody therapy.

21 phalitis and have important implications for antibody therapy.

22 low-grade lymphomas now includes monoclonal antibody therapy.

23 uppression without induction anti-lymphocyte antibody therapy.

24 an be a tumor-specific target for monoclonal antibody therapy.

25 act as effector cells within the context of antibody therapy.

26 nd six received the E. coli infusion without antibody therapy.

27 e antitumor response to antitumor monoclonal antibody therapy.

28 ection and in those receiving antilymphocyte antibody therapy.

29 xicity associated with conventional anti-CD3 antibody therapy.

30 oth eras were steroid resistant and required antibody therapy.

31 as alternatives to polyclonal or monoclonal antibody therapy.

32 potentiate the vaccinal effect of antitumor antibody therapy.

33 istance to anti-PD-L1/anti-CTLA-4 monoclonal antibody therapy.

34 rimary and secondary resistance to anti-EGFR antibody therapy.

35 otential for development of a novel class of antibody therapy.

36 halopathy have occurred following monoclonal antibody therapy.

37 function of monocytes and macrophages during antibody therapy.

38 5% to 44% with the use of anti-IL-2 receptor antibody therapy.

39 dered for testing as adjuvants for antitumor antibody therapy.

40 then FcgammaR activity within the context of antibody therapy.

41 cytic lymphomas, is an attractive target for antibody therapy.

42 immune tolerance mediated by the IL-7Ralpha antibody therapy.

43 activity and a promising target for anti-MIF antibody therapy.

44 ed mice and used it to test human monoclonal antibody therapy.

45 g cells from patients responding to anti-TNF antibody therapy.

46 uggests a possible target for tumor-directed antibody therapy.

47 uman or equine immunoglobulins to monoclonal antibody therapies.

48 f a universal flu vaccine and broad-spectrum antibody therapies.

49 TK11/LKB1-mutated tumors with PD-1-targeting antibody therapies.

50 f HER3 signaling and efficacies of anti-HER3 antibody therapies.

51 s that predict lack of response to anti-EGFR antibody therapies.

52 After cessation of anti-SR-BI-specific antibody therapy, a rise of the viral load was observed.

53 orine, tacrolimus, and anti-IL-2R monoclonal antibody therapy abrogated the effect of a single-dose p

54 ve immunity while the removal of IL-13 using antibody therapy abrogates this effect.

55 A second cycle of anti-HIV-1 monoclonal antibody therapy, administered to two previously treated

56 Monoclonal antibody therapy against alpha4beta-integrin is efficaci

57 for the development of vaccines and passive antibody therapy against C. neoformans.

58 rief course of depletive anti-CD4 monoclonal antibody therapy allowed permanent survival of heart, bu

59 The combination antibody therapy allowed safe achievement of an early hi

60 and tacrolimus, without the use of induction antibody therapy, allows withdrawal of prednisone as ear

61 Antibody therapy also reverses the established lesions o

62 at neither allergen challenge nor monoclonal antibody therapy altered circulating Treg frequency.

63 a are needed on cytokine-specific monoclonal antibody therapies and bronchial thermoplasty.

64 nderstand the untoward effects of monoclonal antibody therapies and other immunomodulatory therapies

65 adnexal MALT lymphoma, especially monoclonal antibody therapy and antibiotic therapy against Chlamydi

66 d an alloantibody response although still on antibody therapy and before the development of a neutral

67 e are promising recent data about anti-HER-2 antibody therapy and other new approaches.

68 ith the emerging role of targeted monoclonal antibody therapy and radioimmunotherapy for orbital and

69 ol group, three patients required monoclonal antibody therapy and two patients required the addition

70 the potential to vastly expand the field of antibody therapy and usher in a new era of cancer vaccin

71 promising option for broad-acting ebolavirus antibody therapy and will accelerate the design of impro

72 ploration of alternative approaches, such as antibody therapy and/or vaccines, for prevention and tre

73 ere rejection (in particular those requiring antibody therapy) and a lower incidence of infection in

74 able on palliative options, bisphosphonates, antibody therapies, and novel targets.

75 plant factors (time to PAK, use of induction antibody therapy, and combinations of immunosuppressive

76 CR2-Fc enhances the therapeutic efficacy of antibody therapy, and the construct may provide particul

77 ease category, previous exposure to anti-GD2 antibody therapy, and tumour MYCN amplification status.

78 was to assess the effects of two monoclonal antibody therapies (anti-OX40L and anti-TSLP) on Treg fr

79 specific adoptive T-cell transfer, agonistic antibody therapy (anti-CD137/4-1BB), and checkpoint bloc

80 (anti-CD137/4-1BB), and checkpoint blockade antibody therapy (anti-PD-L1).

81 Vaccination and passive antibody therapies are critical for controlling infectio

82 Some antibody therapies are currently being evaluated in clin

83 Phase II trials of radiolabeled antibody therapy are providing promising results.

84 osphonate therapy and rank-ligand monoclonal antibody therapy are the most commonly used agents for m

85 ectal carcinoma should not receive anti-EGFR antibody therapy as part of their treatment.

86 motherapy-based regimens, immune modulators, antibody therapy, as well as cellular therapy.

87 equently occurs in patients after polyclonal antibody therapy (ATGAM or thymoglobulin).

88 lowed; previous treatment with EGFR-targeted antibody therapy (but not EGFR-targeted tyrosine-kinase

89 transplantation, growth factor therapy, and antibody therapy, but each proposed therapy has differen

90 Nonlytic anti-CD4 monoclonal antibody therapy can be used to induce transplantation t

91 Although antibody therapy can eliminate tumor cells bearing the t

92 using focused ultrasound in combination with antibody therapy can inhibit growth of breast cancer bra

93 ts show that escape viruses from combination antibody therapy cause less severe CHIKV clinical diseas

94 ll death protein 1 ligand 1 (PD-L1)-specific antibody therapy (checkpoint blockade), and combination

95 cation of human NHL solely with a monoclonal antibody therapy combining rituximab with a blocking ant

96 s was most pronounced with WT FR70 and IgG2a antibody therapy compared with the IgG1 chimeric variant

97 Antibody therapy constitutes a major advance in the trea

98 The addition of methylprednisolone to antibody therapy correlated with improved mouse survival

99 Addition of intratumoral CpG to antibody therapy cured large established tumors and prev

100 Antibody therapies currently target only extracellular a

101 Antibody therapy directed at this target can produce res

102 l fraction of breast cancers, and monoclonal antibody therapy directed toward this antigen is an esta

103 ola virus disease in West Africa, monoclonal antibody therapy (e.g., ZMapp) was utilized to treat pat

104 ffects while receiving an anti-PD-1 or PD-L1 antibody therapy either as monotherapy or in combination

105 of 8ANC195 against HIV-1 in vitro and in an antibody therapy experiment in humanized mice.

106 eas for future development in the monoclonal antibody therapy field.

107 useful in the development of next-generation antibody therapies for cancer.

108 ncreased interest in immune-based monoclonal antibody therapies for different malignancies because of

109 Our findings suggest that antibody therapies for infectious diseases that involve

110 s a major challenge for developing effective antibody therapies for neurological diseases.

111 HIV-1 in humans and provide a model to test antibody therapies for other diseases in NHP.

112 redictors of benefit to anti-EGFR monoclonal antibody therapies for targeted therapy of CRC.

113 rther study of MABp1 anti-interleukin-1alpha antibody therapy for advanced stage cancer is warranted.

114 eart the demonstrable efficacy of our unique antibody therapy for elimination of visceral amyloid.

115 ly encourage the investigation of monoclonal antibody therapy for HIV-1 in humans.

116 sponses to increase the clinical benefits of antibody therapy for human cancer.

117 grin alpha(v)beta3 as a molecular target for antibody therapy for Kaposi's sarcoma (KS).

118 Antibody therapy for neutralization of abused drugs has

119 ery of chemotherapy and anti-HER2 monoclonal antibody therapy for patients with metastatic, HER2-posi

120 erformance status and previous EGFR-targeted antibody therapy for recurrent or metastatic disease.

121 -NL patients (6.9%) requiring antilymphocyte antibody therapy for rejection than in the CsA-SM-treate

122 of CsA-NL patients requiring antilymphocyte antibody therapy for rejection, fewer International Soci

123 ated the development of effective daclizumab antibody therapy for select patients with leukemia/lymph

124 With the exception of monoclonal antibody therapy for the blockade of IgE effector functi

125 support for the development of an anti-CD47 antibody therapy for treatment of human ALL.

126 Addition of anti-IL-2 antibody therapy further improved graft survival, with s

127 ith donor alloantigen combined with anti-CD4 antibody therapy generates CD25+CD4+ T cells that can pr

128 Neutralizing interleukin-4 antibody therapy given only in the newborn period amelio

129 Anti-IL-2 receptor antibody therapy, given intravenously with intervals of

130 However, monoclonal antibody therapy had no additional benefit.

131 However, the development of antibody therapies has focused only on targeting extrace

132 demonstrate that specific depletion of C6 by antibody therapy has a significant effect on guinea pig

133 Anti-CD20 antibody therapy has been a useful medication for managi

134 An ovine polyclonal antibody therapy has been developed against EBOV, named

135 Finally, anti-CD154 antibody therapy has been reported to result in unexpect

136 Indeed, monoclonal antibody therapy has come of age.

137 Monoclonal antibody therapy has emerged as an important therapeutic

138 Although the advent of monoclonal antibody therapy has had a positive effect in the manage

139 Monoclonal antibody therapy has revolutionized cancer treatment by

140 Nerve growth factor (NGF) monoclonal antibody therapy has shown much promise with regard to i

141 Monoclonal antibody therapy has the potential to promote reduced tu

142 Blockbuster antibody therapies have catapulted immune-based approach

143 ntly, immunotherapeutic modalities including antibody therapy have been proposed for the treatment of

144 such as antithymocyte globulin or monoclonal antibody therapy have exhibited hematologic response.

145 Short courses of anti-CD3 monoclonal antibody therapy have provided lasting benefits in recen

146 r-targeted cancer therapies, including armed antibody therapy, have been developed with limited succe

147 n colorectal cancer on response to anti-EGFR antibody therapy, here we perform complete exome sequenc

148 In radiolabeled antibody therapy, imaging and biopsy-based methods are u

149 approximately 9 d after initiation of IGF-1R antibody therapy in 115 patients with refractory or rela

150 understanding of the mechanism of action of antibody therapy in CLL remains limited.

151 anti-tumor necrosis factor (TNF) monoclonal antibody therapy in Crohn's disease has promoted further

152 -5 (mepolizumab) and anti-CD52 (alemtuzumab) antibody therapy in eosinophilic myeloid diseases has ye

153 e complexes could limit the effectiveness of antibody therapy in humans.

154 The decision to use induction antibody therapy in kidney transplantation is often base

155 validate STEAP-1 as an attractive target for antibody therapy in multiple solid tumors and provide a

156 d by PERCIST 1.0 as early as 9 d into IGF-1R antibody therapy in patients with ESFT can predict the O

157 epidermal growth factor receptor monoclonal antibody therapy in patients with metastatic colorectal

158 the mechanisms of action of CD19 monoclonal antibody therapy in pediatric BCP-ALL, we tested an Fc-e

159 tal model suggest the utility of anti-MASP-2 antibody therapy in reperfusion injury and other lectin

160 nstrates the utility of anti-CD14 monoclonal antibody therapy in septic shock and the potential value

161 -to-cell adhesion and has been the target of antibody therapy in several clinical trials.

162 although fewer patients required monoclonal antibody therapy in the cyclosporine group (31% vs. 82%,

163 combining corticosteroid administration with antibody therapy in the mouse model of bubonic plague.

164 vides explanations for the efficacy of IL-2R antibody therapy in uveitis, and suggests that antagonis

165 lovir for the duration of any antilymphocyte antibody therapy, in our kidney and simultaneous pancrea

166 Promising new targets for unconjugated antibody therapy include cellular growth factor receptor

167 Furthermore, IL-7Ralpha antibody therapy increases the frequency of regulatory T

168 Tumor growth resumed on termination of antibody therapy, indicating a cytostatic effect.

169 Combined antibody therapy inhibiting both P-selectin and ICAM-1 v

170 Targeted therapies include targeted antibody therapy; inhibitors of FLT3, KIT, and farnesylt

171 Anti-CD47 antibody therapy initiated on larger tumors inhibited tu

172 oute for delivery of both small-molecule and antibody therapies into microscopic, avascular tumors ty

173 Targeted monoclonal antibody therapy is an intriguing new modality for treat

174 Antibody therapy is currently focused on anti-CD20 (ritu

175 example, it is shown that successful passive antibody therapy is dependent on MHC type because of the

176 studies demonstrate that anti-CD8 monoclonal antibody therapy is effective in both the prevention and

177 Antibody therapy is increasingly recognized as a favored

178 Tac in the settings of renal dysfunction or antibody therapy is not a suitable surrogate of activate

179 inistration of HER-2/neu-specific monoclonal antibody therapy is now widely used for the treatment of

180 Of these, antibody therapy is the most amenable to immediate appli

181 Therefore, anti-TNF antibody therapies may increase the risk of serious infe

182 n addition, the therapeutic efficacy of such antibody therapy may be affected by the delivery route u

183 ipients with serum sickness after polyclonal antibody therapy may benefit from TPE by accelerating th

184 Blockade of TNF-alpha bioactivity by antibody therapy may both preserve cardiac function and

185 s indicate that patients receiving anti-VEGF antibody therapy may have an increased incidence of prot

186 Anti-B7 antibody therapy may have use as an adjunctive agent for

187 e combination of chemotherapy and monoclonal antibody therapy may improve outcomes for patients with

188 ing data also suggest that longer courses of antibody therapy may improve the duration of response.

189 The role of complement in antibody therapy of cancer is in general poorly understo

190 thod to enhance complement activation during antibody therapy of cancer.

191 ach has potential implications in monoclonal antibody therapy of malignancies beyond the combination

192 P4-mediated antibody therapy offers a unique treatment strategy that

193 on of novel approaches, including monoclonal antibody therapy, offers promise for indolent lymphoma,

194 However, myelotoxicity from (90)Y-antibody therapy often correlates poorly with marrow dos

195 ving epidermal growth factor receptor (EGFR) antibody therapy often experience an acneiform rash of u

196 man-primate study, the effects of short-term antibody therapy on 5-year disease progression, virus lo

197 phenformin enhances the effect of anti-PD-1 antibody therapy on inhibiting tumor growth in the BRAF

198 e effects of chronic neu-specific monoclonal antibody therapy on tumor growth and neu protein express

199 costimulation blockade using CD154-specific antibody therapy or by targeting LFA-1 (also known as CD

200 selective depletion of C6 from Lewis rats by antibody therapy prevents hyperacute rejection.

201 Antibody therapies previously approved for inflammatory

202 A 2-week antibody therapy readily cleared HCV RNA from the circul

203 g morphometric analysis of biopsy specimens, antibody therapy reduced the mucosal density of alpha 4

204 IL-7 increases, whereas IL-7Ralpha antibody therapy reduces, the IFN-gamma-producing CD4(+)

205 Monoclonal antibody therapy rendered Fas mutant mice tolerant of mi

206 The use of high-dose 131I antibody therapy requires accurate measurement of normal

207 Furthermore, passive antibody therapy requires continual treatment.

208 OKT3 monoclonal antibody therapy results in an acute clinical syndrome (

209 nded to the addition of anti-CD20 monoclonal antibody therapy (rituximab).

210 l carcinoma who are candidates for anti-EGFR antibody therapy should have their tumor tested for KRAS

211 s with mCRC who are candidates for anti-EGFR antibody therapy should have their tumor tested in a Cli

212 heresis, histone deacetylase inhibitors, and antibody therapies such as alemtuzumab, systemic chemoth

213 g breast cancer often treated with anti-HER2 antibody therapies, such as trastuzumab.

214 pronged tolerogenic mechanisms of IL-7Ralpha antibody therapy suggest a unique disease-modifying appr

215 ical trials have established that monoclonal antibody therapy targeted to PCSK9 may be administered s

216 -associated antigen 4 monoclonal antibodies, antibody therapies targeting prostate-specific membrane

217 for monitoring patients treated with current antibody therapies targeting Region I.

218 e feasibility and efficiency of the combined antibody therapy targeting both P-selection and ICAM-1 v

219 nce can be reliably obtained with monoclonal antibody therapy targeting CD45RB.

220 islet allograft acceptance after monoclonal antibody therapy targeting conceptually distinct molecul

221 tial therapeutic targets; indeed, monoclonal antibody therapy targeting IL-20 is effective in the tre

222 Antibody therapy targeting misfolded proteins is a poten

223 recently generated a combination monoclonal antibody therapy that aborted lethal and arthritogenic d

224 These findings suggest that combination of antibody therapy that depletes antigen-expressing normal

225 lope may reflect a characteristic of anti-B1 antibody therapy that is important for its success.

226 Antibody therapies to prevent or limit filovirus infecti

227 The use of adjunct antibody therapies to treat infectious diseases shows pr

228 Antibody therapy to inhibit either P-selectin or interce

229 Addition of anti-VEGF antibody therapy to standard chemotherapies has improved

230 g rationale for the development of an IL1RAP antibody therapy to target residual CML stem cells.

231 When antibody therapy was initiated in overt leukemia, antibo

232 Induction antibody therapy was not routinely used in either group.

233 Antilymphocyte antibody therapy was not used to treat recurrent rejecti

234 nitoring of anti-tumor necrosis factor alpha antibody therapy was performed over 5 days in an additio

235 Using a murine Her2/neu solid tumor model of antibody therapy, we found that Pam2CSK4 significantly e

236 th this, using a murine solid tumor model of antibody therapy, we show that sFlt-1 is involved in res

237 The therapeutic effects of anti-CD47 antibody therapy were abrogated in T cell-deficient mice

238 acrophages are potent mediators of antitumor antibody therapy, where they engage target cells via Fcg

239 se II clinical trials combining radiolabeled antibody therapy with 5-FU-based treatments are warrante

240 Combining an unconjugated anti-CD20 antibody therapy with a radioimmunoconjugate binding to

241 Dual antibody therapy with bevacizumab and an epidermal growt

242 of real-world patients receiving hepatitis C antibody therapy with LDF/SOF +/- RBV support the prescr

243 alpha (IL10Ralpha) and CD20, the target for antibody therapy with Rituxan.

244 a (ALL) prompted incorporation of monoclonal antibody therapy with rituximab into the intensive chemo